Skip to main content
Fig. 2 | Translational Medicine Communications

Fig. 2

From: iMN041 is an immunotherapeutic and an effective treatment in mouse xenograft models of pancreatic cancer, renal cancer and triple negative breast cancer

Fig. 2

Mice were administered 0.56 mg iMN041 SC qod in FS-14 or PBS (n = 10 per group). At the start of treatment, mean tumor volume +/- standard deviation (SD) was 52 mm3 +/- 15.6. A Graph of Renca tumor volume in iMN041 treated versus control animals. B Survival proportions in treated versus control (25 vs. 16 days, p < 0.0001)

Back to article page

Translational Medicine Communications

ISSN: 2396-832X

Contact us